Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Research Article Volume 5 Issue 6

Physiological and Ethological Impacts of the Antidepressant Escitalopram Studied on Ants as Models

Marie-Claire Cammaerts*

Independent Researcher, Retired from the Biology of Organisms Department, University of Brussels, Belgium

*Corresponding Author: Marie-Claire Cammaerts, Independent Researcher, Retired from the Biology of Organisms Department, University of Brussels, Belgium.

Received: April 05, 2021; Published: May 06, 2021

Abstract

  Humans’ consumption of antidepressants is nowadays increasing. One of the most used for treating severe depressions is escitalopram, an inhibitor of the serotonin recapture, and being so, even if efficient, it may have harmful side effects. Using ants as models, we studied the effect of escitalopram on 13 physiological and ethological traits, the potential adaptation to these effects, the dependence on escitalopram consumption, and the loss of the effect of the drug after weaning. We found that escitalopram impacted the ants’ food consumption, general activity, orientation ability, tactile perception, social relationships, cognition, learning and memory. The ants did not adapt themselves to the impact escitalopram and did not develop dependence on this drug consumption. Young ants seemed to be more affected than the old ones by escitalopram consumption. After weaning, the effect of escitalopram first remained intact during 6 hours, and then slowly decreased in about 30 hours, what accounted for the no dependence on this drug consumption. Most of our results agree with effects observed in humans and with the dosage advised to patients (a dose of 10 mg every 24 hours). A few side effects seen in ants have not (or not yet) been observed in humans and should be thus examined (e.g. effect on social relationships, learning and memory). Habituation to the positive effect of escitalopram, impossible to study on ants, should be checked in humans since in case of its occurrence, humans will increase their drug consumption and therefore the impact of the side effects.

Keywords: Cognition; Food Intake; Learning; Memory; Myrmica sabuleti

References

  1. santemagazine.fr › Actualités › Actualités traitement
  2. Health NIoM. “Prevalence of Major Depressive Episode Among Adults” (2018).
  3. Cammaerts MC., et al. “Physiological and ethological effects of fluoxetine, on ants used as biological models” International Journal of Biology2 (2015): 1-18.
  4. Cammaerts MC., et al. “Ethological and physiological effects of paroxetine, the most consumed antidepressant nowadays: a study on ants as models”. Trends in Entomology 12 (2016): 107-125.
  5. Cammaerts MC., et al. “Physiological and ethological effects of antidepressants: a study using ants as biological models”. International Journal of Pharmaceutical Science Invention2 (2015): 4-24.
  6. Cammaerts MC., et al. “Amitriptyline: physiological and ethological effects of a largely used antidepressant evaluated on ants as biological models”. Acta Scientific Pharmaceutical Sciences.
  7. Bondolfi G., et al. "Psychiatrie: l’escitalopram (Cipralex®)". Revue Médicale Suisse 1 (2003): 22620.
  8. Sanchez C., et al. “The S-enantionner of citalopram (Lu 26-054) is a highly selective and potent serotonin reuptake inhibitor”. Biological Psychiatry 47 (2000): 291.
  9. Owens MJ., et al. “Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetine”. Biological Psychiatry5 (2001): 345-350. 
  10. Gorman JM., et al. “Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: Pooled analysis of placebo-controlled trials”. CNS Spectrum 7 (2002): 40-44.
  11. Kennedy SH., et al. “Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis”. Journal of Psychiatry and Neuroscience2 (2006): 122-131.
  12. Burke WJ., et al. “Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients” Journal of Clinical Psychiatry 63 (2002): 331-336.
  13. Wades A., et al. “Escitalopram 10mg/day is effective and well tolerated in a placebo-controlled study in depression in primlary care”. International Journal of Clinical Psychopharmacology3 (2001): 95-102.
  14. Lepola UM., et al. “Escitalopram (10-20mg/DAY) is effective and well tolerated in a placebo controlled study in depression in primary care”. International Journal of Clinical Psychopharmacology4 (2003): 211-217.
  15. Millet B. "Thérapeutique. Escitalopram versus IRSNa". L’Encéphale3 (2008): 280-283.
  16. Robinson RG., et al. "Escitalopram et psychothérapie de résolution des problèmes dans la prévention des dépressions après accident vasculaire cérébral". JAMA Article Clinique Original20 (2008): 2391-2400.
  17. Bélicard C., et al. “Antidepressant use in demented elderly subjects: current data”. La Revue de Médecine Interne11 (2009): 947-954.
  18. Fish EW., et al. “Anxiolytic-like effects of escitalopram, citalopram, and R-citalopram in maternally separated mouse pups”. Journal of Pharmacology and Experimental Therapeutics2 (2004): 474-480.
  19. Burke WJ. “Escitalopram”. Expert Opinion on Investigational Drugs10 (2002): 1477-1486.
  20. Polychroniou PE., et al. “Temporal profiles and dose-responsiveness of side effects with escitalopram and duloxetine in treatment-naïve depressed adult”. Behavioral Sciences7 (2018): 64.
  21. Cammaerts MC. “Harmful effects of humans’ environmental factors and drugs, and advices for a safer live; a study on ants as models”. World Journal of Pharmaceutical Science1 (2021): 34-45.
  22. Wehner R., et al. "Biologie et physiologie animales". Eds. De Boeck Université, Thieme Verlag, Paris, Bruxelles (1999).
  23. Russell WMS., et al. “The Principles of Humane Experimental Technique”. Johns Hopkins University (2014).
  24. Wolf FW., et al. “Invertebrate models of drug abuse”. Journal of Neurobiology 54 (2003): 161-178.
  25. Andre RG., et al. “Insect Models for Biomedical Research”. In: Nonmammalian Animal Models for Biomedical Research. Woodhead AD, editor, Boca Raton, FL: CRC Press (1989).
  26. Passera L., et al. "Les fourmis: comportement, organisation sociale et évolution". Les Presses Scientifiques du CNRC, Ottawa, Canada (2005).
  27. Cammaerts MC., et al. “Comparative outlook over three Myrmica species’ biotopes and foragers’ know-how” Biologia 69 (2014): 1051-1058.
  28. Cammaerts MC., et al. “Ontogenesis of ants’ cognitive abilities (Hymenoptera, Formicidae)”. Advance Study in Biology 7 (2015): 335-348 + synopsis: 349-350.
  29. Cammaerts MC., et al. “Are ants (Hymenoptera, Formicidae) capable of self recognition?”. Journal of Sciences 7 (2015): 521-532.
  30. Cammaerts MC., et al. “Ants’numerosity ability defined in nine studies”. Journal of Biology and Life Science1 (2020): 121-142.
  31. Cammaerts MC., et al. “Summary of seven more studies on numerosity abilities in an ant, four of them relating to human competence” Journal of Biology and Life Science2 (2020): 296-326.
  32. Cammaerts MC., et al. “Non-numerical distance and size effects in an ant”. Journal of Biology and Life Science 2 (2020): 13-35.
  33. Cammaerts MC., et al. “Weber’s law applied to the ants’ visual perception”. Journal of Biology and Life Science 2 (2020): 36-61.
  34. Cammaerts MC., et al. “Ants can expect the time of an event on basis of previous experiences”. Entomology (2016): 9.
  35. Cammaerts MC., et al. “Spatial expectation of food location in an ant on basis of previous food locations (Hymenoptera, Formicidae)”. Journal of Ethology1 (2016): 9.
  36. Cammaerts MC., et al. “Ants anticipate the following quantity in an arithmetic sequence”. Behavioral Sciences2 (2021): 13.
  37. Cammaerts MC. “Can Myrmica rubra ants use tools or learn to use them?”. International Journal of Biology1 (2018): 1-12.
  38. Cammaerts MC. “Is the largely used analgesic paracetamol without any adverse effects? A study on ants as models”. EC Pharmacology and Toxicology2 (2017): 51-68.
  39. Cammaerts MC., et al. “Ants as models for assessing the effects on health of a CaCO3 + MgCO3 mixture used to decrease gastric hyperacidity” EC Nutrition7 (2018): 500-514.
  40. Cammaerts MC., et al. “Side effects of chloroquine and hydrochloroquine examined on ants as models”. EC Pharmacology and Toxicology11 (2020): 57-82.
  41. Siegel S and Castellan NJ. "Nonparametric statistics for the behavioural sciences”. Singapore: McGraw-Hill (1998).
  42. Cammaerts MC., et al. “An easy and cheap software-based method to assess two-dimensional trajectories parameter”. Belgian Journal of Zoololgy 142 (2012): 145-151.
  43. Cammaerts MC., et al. “Ethological and physiological effects of Sativex, a cannabis-based medicine, examined on ants as models”. Acta Scientific Pharmaceutical Sciences8 (2020): 63-84.
  44. Cammaerts MC. “Performance of the species-typical alarm response in young workers of the ant Myrmica sabuleti is induced by interactions with mature workers”. Journal of Insect Science1 (2014): 234.
  45. Spadone C. “Severe forms of depression: the efficacy of escitalopram”. L’Encéphale2 (2009): 152-159.
  46. Montgomery SA., et al. “Escitalopram (S‐Enantiomer of Citalopram): Clinical Efficacy and Onset of Action Predicted from a Rat Model”. Pharmacology and Toxicology5 (2001): 282-286.
  47. Owley T., et al. “An open-label trial of escitalopram in pervasive developmental disorders”. Journal of the American Academy of Child and Adolescent Psychiatry4 (2005): 343-438.
  48. Otto M., et al. “Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial”. Pain2 (2008): 275-283.
  49. Paul MA., et al. “SSRI effects on psychomotor performance: assessment of citalopram and escitalopram on normal subjects”. Aviation, Space, and Environmental Medicine7 (2007): 693-607.
  50. Drucke B., et al. “Differential effects of escitalopram on attention: a placebo-controlled, double-blind cross-overstudy”. Psychopharmacology213 (2009).
  51. Coskun M., et al. “Escitalopram treatment in preschool children with anxiety disorders: a case series”. Bulletin of Clinical Psychopharmacology3 (2012): 262-267.
  52. Cammaerts MC. “Harmful effects of humans’ environmental factors and drugs, and advices for a safer live; a study on ants as models”. World Journal of Pharmaceutical Science1 (2021): 34-45.

Citation

Citation: Marie-Claire Cammaerts. “Physiological and Ethological Impacts of the Antidepressant Escitalopram Studied on Ants as Models". Acta Scientific Pharmaceutical Sciences 5.6 (2020): 02-16.

Copyright

Copyright: © 2021 Marie-Claire Cammaerts. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days
Impact Factor0.759

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is September 30, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US